Home> Products> Inhibitors> A-192621-CAS 195529-54-5
price inquiry for CAS:195529-54-5, Product:A-192621
For research use only. We do not sell to patients.

A-192621 CAS: 195529-54-5

Category: Inhibitors
Product Name: A-192621
Cat No: I000182
CAS No: 195529-54-5
Synonyms: A-192621; A 192621; A192621; A-192621-1; A-192621.1.;(2R,3R,4S)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-((2,6-diethylphenyl)amino)-2-oxoethyl)-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid
Molecular Formula: C33H38N2O6
Molecular Weight: 558.675
SMILES: O=C([C@H]1[C@H](C2=CC=C(OCCC)C=C2)N(CC(NC3=C(CC)C=CC=C3CC)=O)C[C@@H]1C4=CC=C(OCO5)C5=C4)O
InChI: InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1
InChIKey: LQEHCKYYIXQEBM-FUKIBTTHSA-N
Solubility: Soluble in DMSO, not in water
Target: endothelin-B antagonist
CAS 195529-54-5,A-192621
  • Description

A-192621 is an endothelin-B antagonist. A-192621 markedly enhanced MAP, TPR, and mesenteric, and the renal constrictor effects of ET-1. A-192621 was more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmented constrictor responses to ET-1.

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References


1:Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Wessale JL, Adler AL, Novosad EI, Calzadilla SV, Dayton BD, Marsh KC, Winn M, Jae HS, von Geldern TW, Opgenorth TJ, Wu-Wong JR.Clin Sci (Lond). 2002 Aug;103 Suppl 48:112S-117S. PMID: 12193067
2:Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Wu-Wong JR, Dixon DB, Chiou WJ, Sorensen BK, Liu G, Jae HS, Tasker A, von Geldern TW, Winn M, Opgenorth TJ.Clin Sci (Lond). 2002 Aug;103 Suppl 48:107S-111S. PMID: 12193066
3:Use of A-192621 and IRL-2500 to unmask the mesenteric and renal vasodilator role of endothelin ET(B) receptors. Leung SW, Lim SL, Pang CC, Man RY.J Cardiovasc Pharmacol. 2002 Apr;39(4):533-43. PMID: 11904527
4:Use of A-192621 to provide evidence for involvement of endothelin ET(B)-receptors in endothelin-1-mediated cardiomyocyte hypertrophy. Cullen JP, Bell D, Kelso EJ, McDermott BJ.Eur J Pharmacol. 2001 Apr 13;417(3):157-68. PMID: 11334846
5:Effects of A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic responses to endothelin-1. Brodsky S, Abassi Z, Wessale J, Ramadan R, Winaver J, Hoffman A.J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S311-3. PMID: 11078406


price inquiry for CAS:195529-54-5, Product:A-192621